EA201171429A1 - Противораковое соединение и содержащая его фармацевтическая композиция - Google Patents

Противораковое соединение и содержащая его фармацевтическая композиция

Info

Publication number
EA201171429A1
EA201171429A1 EA201171429A EA201171429A EA201171429A1 EA 201171429 A1 EA201171429 A1 EA 201171429A1 EA 201171429 A EA201171429 A EA 201171429A EA 201171429 A EA201171429 A EA 201171429A EA 201171429 A1 EA201171429 A1 EA 201171429A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
pharmaceutical composition
composition containing
tract
tract compound
Prior art date
Application number
EA201171429A
Other languages
English (en)
Other versions
EA021084B1 (ru
Inventor
Жан-Кристоф Карри
Мишель Шев
Франсуа Клерк
Сесиль Комбо
Сильви Гонтье
Ален Крик
Сильветт Лашо
Лоран Шио
Original Assignee
Санофи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи filed Critical Санофи
Publication of EA201171429A1 publication Critical patent/EA201171429A1/ru
Publication of EA021084B1 publication Critical patent/EA021084B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms

Abstract

Изобретение относится к соединению формулы (I), более конкретно, в его левовращающей форме (1а), в частности, имеющему удельное вращение [α] D=-38, 6±0,7 при концентрации 0,698 мг/мл в метаноле. Соединение может существовать в виде основания или соли присоединения кислоты, в частности фармацевтически приемлемой кислоты. Это соединение является селективным ингибитором киназ Aurora А и В. Оно может также применяться в качестве противоракового средства.
EA201171429A 2009-05-18 2010-05-17 Противораковое соединение и содержащая его фармацевтическая композиция EA021084B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0902392A FR2945535B1 (fr) 2009-05-18 2009-05-18 Compose anticancereux et composition pharmaceutique le contenant
PCT/FR2010/050948 WO2010133794A1 (fr) 2009-05-18 2010-05-17 Compose anticancéreux et composition pharmaceutique le contenant

Publications (2)

Publication Number Publication Date
EA201171429A1 true EA201171429A1 (ru) 2012-05-30
EA021084B1 EA021084B1 (ru) 2015-04-30

Family

ID=40973187

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201171429A EA021084B1 (ru) 2009-05-18 2010-05-17 Противораковое соединение и содержащая его фармацевтическая композиция

Country Status (35)

Country Link
US (2) US9073917B2 (ru)
EP (1) EP2432766B1 (ru)
JP (1) JP5656981B2 (ru)
KR (1) KR20120032483A (ru)
CN (1) CN102459193B (ru)
AR (1) AR076686A1 (ru)
AU (1) AU2010251013B2 (ru)
BR (1) BRPI1012201A2 (ru)
CA (1) CA2762233C (ru)
CL (1) CL2011002930A1 (ru)
CO (1) CO6400138A2 (ru)
CY (1) CY1114850T1 (ru)
DK (1) DK2432766T3 (ru)
EA (1) EA021084B1 (ru)
ES (1) ES2430989T3 (ru)
FR (1) FR2945535B1 (ru)
HK (1) HK1167388A1 (ru)
HR (1) HRP20130959T1 (ru)
IL (1) IL216361A0 (ru)
JO (1) JO2852B1 (ru)
MA (1) MA33356B1 (ru)
ME (1) ME01542B (ru)
MX (1) MX2011012356A (ru)
MY (1) MY152995A (ru)
NZ (1) NZ596464A (ru)
PL (1) PL2432766T3 (ru)
PT (1) PT2432766E (ru)
RS (1) RS53002B (ru)
SG (1) SG176169A1 (ru)
SI (1) SI2432766T1 (ru)
SM (1) SMT201400005B (ru)
TW (1) TWI441822B (ru)
UY (1) UY32644A (ru)
WO (1) WO2010133794A1 (ru)
ZA (1) ZA201108447B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant
FR2967413A1 (fr) * 2010-11-17 2012-05-18 Sanofi Aventis Compose 8-oxo-9-[3-(1h-benzimidazol-2-yloxy)-phenyl]-4,5,6,7,8,9-hexahydro-2h-pyrrolo[3,4-b]quinoline-3-carboxylate d'ethyle, sel, forme cristalline, co-cristal, formulation, procedes de preparation, application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteur des kinases aurora.
ES2719776T3 (es) * 2012-10-12 2019-07-16 Broad Inst Inc Inhibidores de GSK3 y métodos de uso de los mismos
TW201609751A (zh) 2014-07-01 2016-03-16 武田藥品工業股份有限公司 雜環化合物
SG11201909115WA (en) 2017-04-05 2019-10-30 Broad Inst Inc Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036422A1 (en) 1999-11-19 2001-05-25 Abbott Laboratories Tricyclic dihydropyrimidine potassium channel openers
CN1630656A (zh) 2001-02-02 2005-06-22 三菱制药株式会社 二氢吡唑并吡啶化合物及其制药用途
US7037902B2 (en) 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
AU2004264834A1 (en) * 2003-06-13 2005-02-24 Zentaris Gmbh Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof
DK1746097T3 (da) * 2005-07-20 2010-05-25 Aventis Pharma Sa 1,4-dihydropyridin-kondenserede heterocykliske ringe, fremgangsmåde til fremstilling af disse, anvendelse og sammensætninger, der indeholder dem
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant

Also Published As

Publication number Publication date
PL2432766T3 (pl) 2013-12-31
AU2010251013B2 (en) 2015-08-20
JP2012527436A (ja) 2012-11-08
US20150266877A1 (en) 2015-09-24
CO6400138A2 (es) 2012-03-15
AU2010251013A1 (en) 2011-12-08
EP2432766B1 (fr) 2013-07-17
RS53002B (en) 2014-04-30
TW201100418A (en) 2011-01-01
MX2011012356A (es) 2011-12-14
EP2432766A1 (fr) 2012-03-28
JO2852B1 (en) 2015-03-15
JP5656981B2 (ja) 2015-01-21
EA021084B1 (ru) 2015-04-30
CL2011002930A1 (es) 2012-06-29
SMT201400005B (it) 2014-03-07
US20120220621A1 (en) 2012-08-30
HRP20130959T1 (hr) 2013-11-22
AR076686A1 (es) 2011-06-29
SG176169A1 (en) 2011-12-29
ME01542B (me) 2014-04-20
CN102459193B (zh) 2014-08-27
MY152995A (en) 2014-12-31
US9221817B2 (en) 2015-12-29
CA2762233A1 (fr) 2010-11-25
SI2432766T1 (sl) 2013-11-29
CN102459193A (zh) 2012-05-16
DK2432766T3 (da) 2013-10-28
TWI441822B (zh) 2014-06-21
HK1167388A1 (en) 2012-11-30
FR2945535B1 (fr) 2011-06-10
US9073917B2 (en) 2015-07-07
WO2010133794A1 (fr) 2010-11-25
CA2762233C (fr) 2017-11-28
UY32644A (es) 2010-12-31
MA33356B1 (fr) 2012-06-01
KR20120032483A (ko) 2012-04-05
FR2945535A1 (fr) 2010-11-19
PT2432766E (pt) 2013-10-23
BRPI1012201A2 (pt) 2016-04-05
ES2430989T3 (es) 2013-11-22
NZ596464A (en) 2014-01-31
ZA201108447B (en) 2013-01-30
IL216361A0 (en) 2012-01-31
CY1114850T1 (el) 2016-12-14

Similar Documents

Publication Publication Date Title
EA200700601A1 (ru) Производные фениламинопиримидина как ингибиторы bcr-abl
WO2009066152A3 (en) Haloallylamine inhibitors of ssao/vap-1 and uses therefor
EA200601802A1 (ru) Производные морфолина
EA200970149A1 (ru) Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
EA200300354A1 (ru) Хинолиноновые производные в качестве ингибиторов тирозинкиназы
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
EA200600973A1 (ru) ПИРИДО[2,3-d] ПИРИМИДИН-2,4-ДИАМИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE 2
UA94052C2 (ru) Производные пиридазина
EA200970207A1 (ru) Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов
EA200700976A1 (ru) Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой
WO2008143240A1 (ja) 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法
ATE507212T1 (de) Morpholine als 5ht2c-agonisten
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
DK1885187T3 (da) Fremgangsmåde til behandling af lægemiddelresistent cancer
TR201907729T4 (tr) Bir anti-çekirdekleştirici ajan içeren farmasötik bileşim.
MX2008010884A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1.
EA201171429A1 (ru) Противораковое соединение и содержащая его фармацевтическая композиция
EA200970506A1 (ru) Применение индазолметоксиалкановой кислоты для снижения уровней триглицеридов, холестерина и глюкозы
TW200635581A (en) Formulations of azetidine derivatives which can be injected or administered orally
EA200600022A1 (ru) Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU